Premium
Cyclosporine for corticosteroid‐refractory acute generalized exanthematous pustulosis due to hydroxychloroquine
Author(s) -
Castner Nicholas Bradford,
Harris Jessica Crabbe,
Motaparthi Kiran
Publication year - 2018
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.12660
Subject(s) - acute generalized exanthematous pustulosis , medicine , hydroxychloroquine , dermatology , terbinafine , context (archaeology) , corticosteroid , drug , refractory (planetary science) , pharmacology , surgery , covid-19 , itraconazole , antifungal , paleontology , disease , infectious disease (medical specialty) , biology , physics , astrobiology
Acute generalized exanthematous pustulosis most often manifests 1–2 days following exposure to a characteristic drug, such as aminopenicillins, calcium‐channel blockers, or terbinafine. Recovery is usually rapid following drug withdrawal, and systemic corticosteroids represent the historic treatment of choice. Herein, acute generalized exanthematous pustulosis incited by hydroxychloroquine is briefly reviewed: a prolonged latency and recalcitrance to corticosteroids are noteworthy. In this unique context, cyclosporine tapered over several months is an effective therapeutic option.